EASL Recommendations on Treatment of Hepatitis C 2015

Journal of Hepatology

Volumn 63, Issue 1, 2015, Pages 199-236

  Pawlotsky, Jean Michel ^b   Aghemo, Alessio ^b   Back, David ^b   Dusheiko, Geoffrey ^b   Forns, Xavier ^b   Puoti, Massimo ^b   Sarrazin, Christoph ^b  

^a EASL Office   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ACUTE HEPATITIS C; ANEMIA; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; ARTICLE; BLEEDING DISORDER; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CLINICAL DECISION MAKING; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE SEVERITY ASSESSMENT; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DYSPNEA; EUROPEAN UNION; FATIGUE; FOLLOW UP; HEALTH CARE QUALITY; HEMOGLOBINOPATHY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHOCYTOPENIA; MEDICATION COMPLIANCE; MIXED INFECTION; NEUTROPENIA; PATIENT COMPLIANCE; PHYSICIAN; PRIORITY JOURNAL; RETREATMENT; SKIN MANIFESTATION; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; DISEASE MANAGEMENT; EUROPE;

DISEASE MANAGEMENT; EUROPE; HEPATITIS C; HUMANS;

EID: 84931560807     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.025     Document Type: Article

References (138)

1. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
2. Y. Arase, M. Kobayashi, F. Suzuki, Y. Suzuki, Y. Kawamura, N. Akuta, and et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C Hepatology 57 2013 964 973
3. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, F. Lammert, and et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
4. D. Alsop, Z. Younossi, M. Stepanova, and N.H. Afdhal Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 naive patients treated with ledipasvir and sofosbuvir Hepatology 60 2014 221A
5. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
6. N. Antaki, A. Craxi, S. Kamal, R. Moucari, S. Van der Merwe, S. Haffar, and et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report Liver Int 30 2010 342 355
7. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, and et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
8. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, and et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
9. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, and et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
10. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, and et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
11. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
12. A. Doab, C. Treloar, and G.J. Dore Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia Clin Infect Dis 40 2005 S313 S320
13. D.M. Jensen, J.G. O'Leary, P.J. Pockros, K.E. Sherman, P.Y. Kwo, M.E. Mailliard, and et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort Hepatology 60 2014 219A
14. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, and et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
15. J. Andrews, G. Guyatt, A.D. Oxman, P. Alderson, P. Dahm, Y. Falck-Ytter, and et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J Clin Epidemiol 66 2013 719 725
16. S. Chevaliez, and J.M. Pawlotsky Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes Best Pract Res Clin Gastroenterol 22 2008 1031 1048
17. S. Kamili, J. Drobeniuc, A.C. Araujo, and T.M. Hayden Laboratory diagnostics for hepatitis C virus infection Clin Infect Dis 55 2012 S43 S48
18. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, L. Leclere, and et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
19. M.G. Swain, M.Y. Lai, M.L. Shiffman, W.G. Cooksley, S. Zeuzem, D.T. Dieterich, and et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
20. L. Castera, G. Sebastiani, B. Le Bail, V. de Ledinghen, P. Couzigou, and A. Alberti Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C J Hepatol 52 2010 191 198
21. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, M. Haaser, and et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
22. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
23. M.T. Huisman, J. Snoeys, J. Monbaliu, M.A. Martens, V.J. Sekar, and A. Raoof In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters Hepatology 52 2010 461A
24. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
25. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, and et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
26. P. Mishra, J. Florian, K. Qi, W. Zeng, L.K. Naeger, E. Donaldson, and et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin Gastroenterology 147 2014 1196 1200
27. S. Pol, M. Sulkowski, T. Hassanein, E. Gane, N. Liyun, H. Ho, and et al. Successful retreatment with sofosbuvir of HCV genotype 1-infected patients who failed prior therapy with peginterferon plus ribavirin plus one or two additional direct-acting antiviral agents J Hepatol 60 2014 S23
28. D. Dieterich, B.R. Bacon, S.L. Flamm, K.V. Kowdley, S. Milligan, N. Tsai, and et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population Hepatology 60 2014 220A
29. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, V.V. Rafalsky, and et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
30. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, Y. Horsmans, and et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
31. D. Dieterich, J.K. Rockstroh, C. Orkin, F. Gutierrez, M.B. Klein, J. Reynes, and et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study Clin Infect Dis 59 2014 1579 1587
32. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.P. Bronowicki, P. Andreone, and et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679
33. K.R. Reddy, S. Zeuzem, F. Zoulim, O. Weiland, A. Horban, C. Stanciu, and et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial Lancet Infect Dis 15 2015 27 35
34. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
35. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, and et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
36. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, and et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
37. K.S. Townsend, A. Osinusi, A.K. Nelson, A. Kohli, C. Gross, M.A. Polis, and et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on and off antiretroviral therapy: results from the NIAID ERADICATE trial Hepatology 60 2014 240A
38. M. Bourlière, M.S. Sulkowski, M. Omata, S. Zeuzem, J.J. Feld, E. Lawitz, and et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin Hepatology 60 2014 239A
39. M. Bourlière, J.P. Bronowicki, V. de Ledinghen, C. Hézode, F. Zoulim, P. Mathurin, and et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy Hepatology 60 2014 1271A
40. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, D. Crawford, and et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
41. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, and et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
42. D.L. Wyles, M.S. Sulkowski, J.J. Eron, R. Trinh, J. Lalezari, J. Slim, and et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin Hepatology 60 2014 1136A
43. S. Zeuzem, I.M. Jacobson, T. Baykal, R.T. Marinho, F. Poordad, M. Bourliere, and et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
44. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, A. Maieron, and et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
45. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
46. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, and et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
47. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
48. R. Esteban, L. Nyberg, J. Lalezari, L. Ni, B. Doehle, B. Kanwar, and et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy J Hepatol 60 2014 S4
49. E. Lawitz, F. Poordad, D.M. Brainard, R.H. Hyland, D. An, W.T. Symonds, and et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study Hepatology 58 2013 1380A
50. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, A.M. Sheikh, and et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
51. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 Gastroenterology 370 2014 1993 2001
52. D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, and et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study Hepatology 61 2015 1127 1135
53. C. Moreno, C. Hezode, P. Marcellin, S. Bourgeois, S. Francque, D. Samuel, and et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4 J Hepatol 62 2015 1047 1055
54. R. Kapoor, A. Kohli, S. Sidharthan, Z. Sims, T.L. Petersen, A. Osinusi, and et al. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial Hepatology 60 2014 321A
55. S. Pol, K.R. Reddy, T. Baykal, C. Hezode, T. Hassanein, P. Marcellin, and et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results Hepatology 60 2014 1129A
56. E.J. Gane, R.H. Hyland, D. An, E.S. Svarovskaia, P.S. Pang, W.T. Symonds, and et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection Hepatology 60 2014 1274A
57. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31
58. C. Sarrazin, M.L. Shiffman, S.J. Hadziyannis, A. Lin, G. Colucci, H. Ishida, and et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy J Hepatol 52 2010 832 838
59. J. Vermehren, A. Kau, B.C. Gartner, R. Gobel, S. Zeuzem, and C. Sarrazin Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification J Clin Microbiol 46 2008 3880 3891
60. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237 S244
61. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales Jr., and et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
62. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, and et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
63. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, and et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
64. M.L. Shiffman, J. Salvatore, S. Hubbard, A. Price, R.K. Sterling, R.T. Stravitz, and et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371 379
65. A. Soza, J.E. Everhart, M.G. Ghany, E. Doo, T. Heller, K. Promrat, and et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36 2002 1273 1279
66. N.H. Afdhal, D.T. Dieterich, P.J. Pockros, E.R. Schiff, M.L. Shiffman, M.S. Sulkowski, and et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
67. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, D.T. Dieterich, and et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
68. M.S. Sulkowski, F. Poordad, M.P. Manns, J.P. Bronowicki, R.K. Reddy, S.A. Harrison, and et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial Hepatology 57 2013 974 984
69. S.M. Alavian, and S.H. Aalaei-Andabili Education by a nurse increases the adherence to therapy in chronic hepatitis C patients Clin Gastroenterol Hepatol 10 2012 203
70. J.L. Rodis, and P. Kibbe Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy Gastroenterol Nurs 33 2010 368 373
71. B.S. Anand, S. Currie, E. Dieperink, E.J. Bini, H. Shen, S.B. Ho, and et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study Gastroenterology 130 2006 1607 1616
72. P. Bruggmann, M. Dampz, T. Gerlach, L. Kravecz, and L. Falcato Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study Drug Alcohol Depend 110 2010 167 171
73. C. Le Lan, A. Guillygomarc'h, H. Danielou, G. Le Dreau, F. Laine, C. Vedeilhie, and et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse J Hepatol 56 2012 334 340
74. L. Siu, J. Foont, and J.R. Wands Hepatitis C virus and alcohol Semin Liver Dis 29 2009 188 199
75. M. Backmund, K. Meyer, and B.R. Edlin Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users Clin Infect Dis 39 2004 1540 1543
76. S.L. Currie, J.C. Ryan, D. Tracy, T.L. Wright, S. George, R. McQuaid, and et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus Drug Alcohol Depend 93 2008 148 154
77. O. Dalgard Follow-up studies of treatment for hepatitis C virus infection among injection drug users Clin Infect Dis 40 2005 S336 S338
78. J. Grebely, E. Knight, T. Ngai, K.A. Genoway, J.D. Raffa, M. Storms, and et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users J Gastroenterol Hepatol 25 2010 1281 1284
79. J. Grebely, S.T. Pham, G.V. Matthews, K. Petoumenos, R.A. Bull, B. Yeung, and et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection Hepatology 55 2012 1058 1069
80. R.J. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, S.C. Gordon, and et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
81. F. McPhee, D. Hernandez, F. Yu, J. Ueland, A. Monikowski, A. Carifa, and et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir Hepatology 58 2013 902 911
82. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E.Z. Zhang, J. Spanks, and et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
83. C. Wang, J.H. Sun, D.R. O'Boyle 2nd, P. Nower, L. Valera, S. Roberts, and et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir Antimicrob Agents Chemother 57 2013 2054 2065
84. O. Lenz, T. Verbinnen, B. Fevery, L. Tambuyzer, L. Vijgen, M. Peeters, and et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies J Hepatol 62 2015 1008 1014
85. P. Krishnan, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, M. Irvin, and et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials Hepatology 60 2014 1134A
86. C. Sarrazin, H. Dvory-Sobol, E.S. Svarovskaia, B. Doehle, J.F. McCarville, P.S. Pang, and et al. Baseline and post-baseline resistance analyses of Phase 2/3 studies of ledipasvir/sofosbuvir ± RBV Hepatology 60 2014 1128A
87. D.L. Wyles, P.J. Pockros, J.C. Yang, Y. Zhu, P.S. Pang, J.G. McHutchison, and et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all-oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks Hepatology 60 2014 317A
88. N. Afdhal, G. Everson, J.L. Calleja, G. McCaughan, W.T. Symonds, J. Denning, and et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety J Hepatol 60 2014 S28
89. S.L. Flamm, G.T. Everson, M. Charlton, J.M. Denning, S. Arterburn, T. Brandt-Sarif, and et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study Hepatology 60 2014 320A
90. C. Moon, K.S. Jung, D.Y. Kim, O. Baatarkhuu, J.Y. Park, B.K. Kim, and et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin Dig Dis Sci 60 2015 573 581
91. R.L. Morgan, B. Baack, B.D. Smith, A. Yartel, M. Pitasi, and Y. Falck-Ytter Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies Ann Intern Med 158 2013 329 337
92. A.K. Singal, D.H. Freeman Jr., and B.S. Anand Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma Aliment Pharmacol Ther 32 2010 851 858
93. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, M. Navasa, and et al. Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
94. E. Gane, and H. Pilmore Management of chronic viral hepatitis before and after renal transplantation Transplantation 74 2002 427 437
95. M.P. Curry, X. Forns, R.T. Chung, N.A. Terrault, R. Brown Jr., J.M. Fenkel, and et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study Gastroenterology 148 2015 100 107
96. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
97. M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, D. Carrasco, and et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
98. A. Blasco, X. Forns, J.A. Carrion, J.C. Garcia-Pagan, R. Gilabert, A. Rimola, and et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
99. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, R. Neuhaus, and et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
100. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayon, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
101. M. Gambato, S. Lens, M. Navasa, and X. Forns Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation J Hepatol 61 2014 S120 S131
102. M. Charlton, E. Gane, M.P. Manns, R.S. Brown Jr., M.P. Curry, P.Y. Kwo, and et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterology 148 2015 108 117
103. R.K. Reddy, G.T. Everson, S.L. Flamm, J.M. Denning, S. Arterburn, T. Brandt-Sarif, and et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective, multicenter study Hepatology 60 2014 200A 201A
104. P.S. Mantry, P.Y. Kwo, E. Coakley, H.S. Te, H.E. Vargas, R.S. Brown, and et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/r/ombitasvir plus dasabuvir plus ribavirin Hepatology 60 2014 298A
105. R.S. Brown, K.R.J. Reddy, J.G. O'Leary, A. Kuo, G. Morelli, R.T. Stravitz, and et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study Hepatology 60 2014 1269A
106. V. Leroy, J. Dumortier, A. Coilly, M. Sebagh, C. Fougerou-Leurent, S. Radenne, and et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV recurrence after liver transplantation: the ANRS CO23 CUPILT study Hepatology 60 2014 207A
107. A. Potthoff, T. Berg, and H. Wedemeyer Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin Scand J Gastroenterol 44 2009 1487 1490
108. D.R. Scott, J.K. Wong, T.S. Spicer, H. Dent, F.K. Mensah, S. McDonald, and et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand Transplantation 90 2010 1165 1171
109. L.B. Van Wagner, T. Baker, S.N. Ahya, J.P. Norvell, E. Wang, and J. Levitsky Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation J Hepatol 51 2009 874 880
110. J.B. Orens, M. Estenne, S. Arcasoy, J.V. Conte, P. Corris, J.J. Egan, and et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 745 755
111. S. Darke, S. Kaye, and J. Duflou Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes Addiction 101 2006 1771 1777
112. J. Grebely, J.D. Raffa, C. Lai, T. Kerr, B. Fischer, M. Krajden, and et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents J Viral Hepat 18 2011 32 41
113. H. Hagan, E.R. Pouget, D.C. Des Jarlais, and C. Lelutiu-Weinberger Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place Am J Epidemiol 168 2008 1099 1109
114. P.K. Nelson, B.M. Mathers, B. Cowie, H. Hagan, D. Des Jarlais, D. Horyniak, and et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews Lancet 378 2011 571 583
115. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567
116. J. Grebely, and G.J. Dore What is killing people with hepatitis C virus infection? Semin Liver Dis 31 2011 331 339
117. N.K. Martin, P. Vickerman, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and M. Hickman Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 54 2011 1137 1144
118. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
119. R. van Heeswijk, A. Vandevoorde, P. Verboven, G. Boogaerts, E. De Paepe, R. van Solingen-Ristea, and et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir J Hepatol 54 2011 S491
120. X. Luo, J. Trevejo, R. Van Heeswijk, and V. Garg No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers Global Antivir J 7 2011 116 117
121. K. Deterding, N. Gruner, P. Buggisch, J. Wiegand, P.R. Galle, U. Spengler, and et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial Lancet Infect Dis 13 2013 497 506
122. S.M. Kamal Acute hepatitis C: a systematic review Am J Gastroenterol 103 2008 1283 1297
123. M.U. Mondelli, A. Cerino, and A. Cividini Acute hepatitis C: diagnosis and management J Hepatol 42 2005 S108 S114
124. T. Santantonio, J. Wiegand, and J.T. Gerlach Acute hepatitis C: current status and remaining challenges J Hepatol 49 2008 625 633
125. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
126. J. Wiegand, E. Jackel, M. Cornberg, H. Hinrichsen, M. Dietrich, J. Kroeger, and et al. Long-term follow-up after successful interferon therapy of acute hepatitis C Hepatology 40 2004 98 107
127. European ATNAHCICP. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference AIDS 25 2011 399 409
128. T. Santantonio, M. Fasano, E. Sagnelli, P. Tundo, S. Babudieri, P. Fabris, and et al. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin Hepatology 59 2014 2101 2109
129. A. Mangia, R. Santoro, M. Copetti, M. Massari, V. Piazzolla, E. Spada, and et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection J Hepatol 59 2013 221 228
130. D.S. Fierer, D.T. Dieterich, M.P. Mullen, A.D. Branch, A.J. Uriel, D.C. Carriero, and et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men Clin Infect Dis 58 2014 873 879
131. C. Camma, P. Almasio, and A. Craxi Interferon as treatment for acute hepatitis C. A meta-analysis Dig Dis Sci 41 1996 1248 1255
132. J.T. Gerlach, H.M. Diepolder, R. Zachoval, N.H. Gruener, M.C. Jung, A. Ulsenheimer, and et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80 88
133. J.M. Micallef, J.M. Kaldor, and G.J. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 2006 34 41
134. T. Poynard, C. Regimbeau, R.P. Myers, T. Thevenot, V. Leroy, P. Mathurin, and et al. Interferon for acute hepatitis C Cochrane Database Syst Rev 1 2002 CD000369
135. H. Hofer, T. Watkins-Riedel, O. Janata, E. Penner, H. Holzmann, P. Steindl-Munda, and et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load Hepatology 37 2003 60 64
136. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
137. J.M. Pawlotsky Hepatitis C treatment: the data flood goes on: an update from the Liver Meeting 2014 Gastroenterology 148 2015 468 479